SCHEMBL25366273

SCHEMBL25366273

COc1ccc(C[C@@H]2CNC(=S)N2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.41
PDE4A P27815 2/20 0.41
PDE4D Q08499 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TNF P01375 1/20 0.41
MAPT P10636 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
NFKB1 P19838 1/20 0.41
TACR2 P21452 1/20 0.41
GLA P06280 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP2D6 P10635 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366278 1.00 MAPK1 (0.41) MAPK1PDE4APDE4DLMNAMEN1
SCHEMBL2847339 0.83 MAPK1 (0.42) MAPK1PDE4APDE4DLMNAMEN1
SCHEMBL25366852 0.82 SMN1; SMN2 (0.36) MAPK1PDE4APDE4DLMNAMEN1
SCHEMBL25365743 0.79 ALDH1A1 (0.36) MEN1KMT2ATACR2ALDH1A1
SCHEMBL25367156 0.79 MEN1 (0.37) MEN1KMT2ACYP3A4CYP2D6ALDH1A1
SCHEMBL1598073 0.78 MEN1 (0.47) MEN1KMT2AALDH1A1
SCHEMBL21678055 0.78 CYP2D6 (0.49) MAPK1LMNAMEN1KMT2ACYP2D6
SCHEMBL23802727 0.76 CYP2D6 (0.48) MAPK1LMNAMEN1KMT2ACYP2D6
SCHEMBL23802816 0.76 CYP2D6 (0.48) MAPK1LMNAMEN1KMT2ACYP2D6
SCHEMBL11482190 0.75 GLA (0.45) MAPK1LMNAMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 MAPK1 1156/4885PDE4A 280/4885PDE4D 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.